Related Party Transactions

3 Months Ended

Mar. 31, 2023

Master Services agreements with drug discovery companies affiliated with David Grainger

Certain Centessa subsidiaries entered into Master Services agreements with certain drug discovery companies affiliated with David Grainger, who was appointed as the Company’s Chief Innovation Officer in October 2021. These companies include RxCelerate Limited, RxBiologics Limited and The Foundry (Cambridge) Limited, of which David Grainger is a director and shareholder. The Company incurred research and development costs associated with these contracts as follows in the consolidated statements of operations and comprehensive loss (amounts in thousands):


	Three Months Ended March 31, 2023		Three Months Ended March 31, 2022
Research and development	$	2,322	$	1,699